Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna CGM, Diabetes Supplies Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0070

    Diabetes Tests, Programs and Supplies

    Customize your policy alerts

    Sign up for Aetna Policy 0070 alerts

    Get alerted when Policy 0070 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage, limitations, and coding for diabetes-related tests, self-care programs, continuous glucose monitoring, supplies, and related devices for members with diabetes.

    Policy Summary
    PayerAetna
    PolicyDiabetes Tests, Programs and Supplies
    Policy CodePolicy 0070
    Change TypeNo material changes
    Effective DateOct 20, 1995
    Last ReviewAug 9, 2023
    Next Review DateJan 11, 2024
    Key ActionWhen ordering CGM or implantable sensors, ensure selection criteria and required documentation are met and submit prior authorization per plan if applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~218references cited
    01/11/2024next review
    1995-10-20effective date
    100/300supply limits
    extensivecode lists

    Coverage Criteria and Medical Necessity

    Diabetes Self-Care Programs (Medical Necessity)

    Covered when ALL of the following are met

    Self-care program coverage criteria: The outpatient diabetes self-care program consists of services provided by recognized healthcare professionals (e.g., physicians, registered dieticians, registered nurses, registered pharmacists); and the program is designed to educate the member about medically necessary diabetes self-care; and the program is ordered by the physician treating the member's diabetes with a statement signed by the physician that the service is needed.

    Program must meet all listed elements to be considered medically necessary.

    Continuous Glucose Monitoring - Short-term diagnostic use

    Covered when ANY of the following diagnostic indications are present and duration is 72 hours to 1 week (max 2 periods per 12 months)

    Hypoglycemia unawareness: Short-term (72 hours to 1 week) professional/diagnostic CGM is used for persons with diabetes with hypoglycemia unawareness who are unresponsive to conventional insulin dose adjustment.
    Policy Summary
    PayerAetna
    PolicyDiabetes Tests, Programs and Supplies
    Policy CodePolicy 0070
    Change TypeNo material changes
    Effective DateOct 20, 1995
    Last ReviewAug 9, 2023
    Next Review DateJan 11, 2024
    Key ActionWhen ordering CGM or implantable sensors, ensure selection criteria and required documentation are met and submit prior authorization per plan if applicable.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding: CPT, HCPCS, and ICD-10 GuidanceProvider Actions: Authorization, Documentation, and BillingBackground and Evidence SummaryDefinitions and Key TermsPolicy Dates and Revision History
    72 hours to 1 week; no more than 2 periods within 12 months

    Documentation should support unresponsiveness to conventional insulin adjustment and number of monitoring periods.

    Recurrent daily hypo/hyperglycemia: Short-term (72 hours to 1 week) professional/diagnostic CGM for repeated hypoglycemia (less than 50 mg/dL) and hyperglycemia (greater than 150 mg/dL) occurring at the same time each day.72 hours to 1 week; no more than 2 periods within 12 months

    Used when conventional SMBG has not identified/control these patterns.

    Diagnostic evaluation of nesidioblastosis/PHHI: Short-term (72 hours to 1 week) CGM to assist in the diagnosis of primary islet cell hypertrophy (nesidioblastosis) or persistent hyperinsulinemic hypoglycemia of infancy (PHHI) in symptomatic persons.72 hours to 1 week; no more than 2 periods within 12 months

    Appropriate when clinical features suggest congenital or persistent hypoglycemia; document symptoms and indication.

    Continuous Glucose Monitoring - Long-term therapeutic use

    Covered when ALL of the following are met

    Long-term CGM adult criteria: Adult (>= 18 years) with type 1 or type 2 diabetes who is using an intensive insulin regimen (multiple (3 or more) daily injections or insulin pump therapy); AND the member is either not meeting glycemic targets or experiencing hypoglycemia (including hypoglycemic unawareness).>1 week

    Continued coverage requires demonstrated improved glycemic control or decreased hypoglycemia while using CGM, or prescriber assessment of adherence every 6 months.

    Experimental/Investigational determinations

    Not covered (considered experimental/investigational) for these indications

    Experimental CGM uses: Long-term (therapeutic) CGM for persons with type 2 diabetes not using intensive insulin regimens; nesidioblastosis (primary islet cell hypertrophy) when used long-term; routine use for neonatal hypoglycemia screening/management; and monitoring of non-diabetic persons after gastric bypass surgery.

    These indications lack sufficient evidence of clinical benefit per policy.

    Special DME: Blood glucose monitors for visual impairment or manual dexterity

    Covered when ANY of the following are met

    Visual impairment: Reflectance (voice-enabled) blood glucose meters and specially arranged supplies as durable medical equipment for legally blind persons (best corrected visual acuity <20/200).

    Device provided as DME when criteria for legal blindness are met.

    Manual dexterity impairment: Blood glucose monitors with integrated lancing/blood sample provided as DME for persons who are legally blind OR have manual dexterity impairment severe enough to require the special monitoring system.

    Physician recommendation and documentation required.

    Alternate Site Blood Glucose Monitors

    Covered when ANY of the following are met

    Children under 12: Alternate-site blood glucose monitors as DME when recommended by the physician for children below the age of 12 years.

    Physician recommendation must document reason for alternate site testing.

    Pain sensitivity or callused fingertips: Alternate-site monitors as DME for persons who have used conventional meters for at least 1 month and who are non-compliant with testing due to pain sensitivity or heavily callused fingertips.>30 days of prior conventional meter use

    Document prior use and reason for alternate-site necessity.

    Device/procedure coverage contingent on selection criteria

    Coverage of specific CGM procedures, implantable sensors, and supplies is contingent on meeting selection criteria referenced in the policy.

    General requirement: Use of listed CPT/HCPCS/proprietary device codes (eg, 95249, 95250, 95251, 0446T-0448T, G0308-G0309, A9276-A9278, A4239, E2103, S1030-S1037) is covered only when the policy's selection/medical necessity criteria are met and appropriate documentation accompanies claims.

    Providers must supply documentation linking billed code to selection criteria and clinical indication.

    Diagnosis-based coverage logic

    ICD-10 diagnoses guide coverage when selection criteria are met; some diagnoses are explicitly not covered for listed CPB indications.

    Covered diagnoses with criteria: ICD-10 ranges such as E08.00–E13.9 (diabetes mellitus), E10.10–E10.9 (type 1 diabetes), E11.00–E11.9 (type 2 diabetes), and E74.00–E74.09 (glycogen storage diseases) may be covered when the policy's selection criteria are satisfied.

    Type 2 diabetes codes are considered investigational for persons not using intensive insulin regimens unless selection criteria met.

    Not covered diagnoses: ICD-10 codes E16.9 (disorder of pancreatic internal secretion, unspecified/nesidioblastosis) and P70.3–P70.4 (iatrogenic and other neonatal hypoglycemia) are listed as not covered for the CPB indications.

    Claims with these principal diagnoses may be denied for listed CPB indications.

    Adult type 1 diabetes — supported use

    Evidence-supported coverage focus

    Adults with type 1 diabetes on intensive insulin regimens: CGM in conjunction with intensive insulin regimens is supported to lower A1C in adults with type 1 diabetes not meeting glycemic targets and may be useful for hypoglycemia unawareness; robust diabetes education, training, and assessment of readiness are required.per ADA guidance

    Assess individual readiness and provide education/support prior to prescribing CGM.

    Type 2 diabetes — conditional/limited evidence

    Limited or conditional coverage

    Type 2 diabetes: CGM may provide modest short-term A1C reductions in select insulin-treated adults with type 2 diabetes (eg, multiple daily injections), but generalizability and long-term outcome benefits are uncertain; select patients may be considered when meeting policy criteria.mean A1C reductions reported ~0.3% in trials

    Consider patient selection, ability to act on CGM data, and adherence.

    Children, adolescents, and pregnancy — insufficient evidence

    Subgroups with insufficient evidence

    Children, adolescents, pregnant women: Available randomized and technology-assessment evidence does not demonstrate consistent benefit for children, adolescents, or pregnant women; device adherence and study limitations are concerns and broader use should await further evidence.no conclusive HbA1c benefit across trials

    Technology assessments recommend further study before broad use in these subgroups.

    Professional/diagnostic CGM use

    Diagnostic/professional use

    Short-term professional (diagnostic) CGM use: Professional/diagnostic short-term CGM can detect unrecognized (especially nocturnal) hypoglycemia and shorten duration of hypoglycemia, and may be used to guide therapy adjustments.short-term monitoring (eg, 72 hours)

    Diagnostic yield examples include detection rates of 46–62.5% in small series; clinical significance of reduced duration of asymptomatic hypoglycemia is uncertain.

    Clinical uses supported by cited evidence

    Evidence-based clinical applications described in the document include:

    Diagnostic/professional CGM for unrecognized hypoglycemia: Professional (short-term) CGM can detect unrecognized and nocturnal hypoglycemia in persons with diabetes (type 1 and type 2) and has diagnostic yield reported in small series and trials.short-term monitoring (eg, 72 hours)

    Studies are often small and short-duration; long-term outcome impact not established.

    Flash glucose monitoring (FGM) for ambulatory assessment: Flash glucose monitoring (eg, FreeStyle Libre) is associated with increased scan frequency and improved estimated glycemic metrics in real-world datasets and trials, but accuracy is variable, particularly at low glucose values.device wear periods ~10–14 days

    Users showed high satisfaction; caution when making insulin dosing decisions due to occasional >20–30% deviations.

    CGM in glycogen storage disease and congenital hyperinsulinism: CGM has utility to identify asymptomatic hypoglycemia and guide outpatient dietary/medical management in patients with glycogen storage diseases and congenital hyperinsulinism in small observational studies.typically 72-hour or repeated monitoring

    Data are limited by small sample sizes; useful as adjunctive monitoring tool.

    Closed-loop/artificial pancreas systems: Closed-loop systems that integrate CGM, insulin pump, and control algorithm can reduce nocturnal hypoglycemia (eg, threshold-suspend systems) though earlier research devices remain primarily investigational; modern systems may be acceptable alternatives for medically necessary indications per device labeling and guidance.NA

    Threshold-suspend devices (eg, MiniMed 530G) have demonstrated reduced nocturnal hypoglycemia in RCTs.

    Continuous glucose monitoring in neonates

    Evidence summary and uncertainty

    Neonatal CGM evidence: CGM has been reported reliable and tolerable in neonates, including very preterm infants, but interpretation of low interstitial glucose values and treatment thresholds is unclear; further study is needed before routine clinical use.

    UpToDate reviews cite reliability but state clinical significance of readings is uncertain.

    Artificial pancreas / threshold-suspend systems

    Summarized clinical trial evidence

    Threshold-suspend efficacy: Sensor-augmented pump therapy with a threshold-suspend (low glucose suspend) feature reduced nocturnal hypoglycemia (eg, 37.5% lower nocturnal hypoglycemic AUC; 31.8% fewer nocturnal events) over 3 months versus sensor-augmented pump without suspend.

    ASPIRE/Bergenstal randomized trial demonstrated these reductions without increasing A1C.

    Regulatory status: MiniMed 530G (threshold-suspend system) received FDA premarket approval (PMA) and is an example of an approved threshold-suspend device.

    Device labeling and approval referenced in background.

    GlucoWatch Biographer

    Device accuracy and outcome data

    GlucoWatch accuracy limitations: GlucoWatch Biographer measurements differed from fingerstick results by more than 30% up to one-third of the time; it requires calibration with fingerstick each time worn and should not be used alone to make insulin dosing decisions.

    Randomized trials did not demonstrate improved glycemic control or reduced severe hypoglycemia in children when GlucoWatch was added.

    Clinical outcomes: RCT evidence failed to show benefit for GlucoWatch in pediatric type 1 diabetes (eg, Chase et al., n=200); TEC/CTAF assessments concluded insufficient evidence of impact on health outcomes.

    Device considered to supplement, not replace fingerstick testing.

    Alternate-site blood glucose monitoring

    Accuracy and practical concerns

    Alternate-site testing limitations: Alternate-site blood glucose testing may be less painful but can be harder to obtain, may cause bruising or increased infection risk, and may not reflect systemic glucose during rapid changes (eg, postprandial or exercise).

    No evidence that alternate-site testing improves compliance over fingertip testing.

    Home A1C and PDA-based monitoring

    Outcome evidence

    Home A1C monitors: Home glycated hemoglobin (A1C) monitors lack prospective studies demonstrating improved compliance or clinically significant benefits versus laboratory A1C testing; ADA recommends A1C testing no more frequently than quarterly.

    Home A1C testing unlikely to improve outcomes; office/lab testing allows provider interpretation.

    PDA-based meters: PDA-based blood glucose monitors show feasibility and acceptability but no published evidence that they improve clinical outcomes versus standard meters.

    Use may aid self-management but outcome benefit unproven.

    Infrared foot thermometry for ulcer prevention

    Evidence for home temperature monitoring in high-risk patients

    Target population: Patients at high risk for diabetic foot ulceration (eg, neuropathy with deformity or prior ulcer/amputation) were studied in RCTs of home infrared thermometry.

    Studies enrolled high-risk categories (risk 2 or 3).

    Intervention: Daily home infrared skin temperature measurements at multiple foot sites with instruction to reduce activity and contact care when a >=4°F side-to-side difference is detected.>= 4 degrees Fahrenheit side-to-side difference

    TempTouch device protocol used in trials.

    Outcomes: Enhanced therapy groups using thermometry had significantly fewer foot complications/ulcers versus standard care in multiple RCTs (eg, reduced ulcer rates at 6–18 months).

    Lavery and Armstrong trials reported lower ulcer incidence with thermometry-guided action.

    Evidence certainty: Although RCTs reported benefit, reviewers note potential behavior change effects and recommend further research; overall certainty and generalizability are not definitive.

    Guideline authors caution interpreting results and recommend standard screening first.

    General coverage stance for reviewed devices

    Covered when evidence demonstrates clinical effectiveness and impact on management or outcomes; otherwise investigational or research-use devices are not covered.

    Standard screening and care first: Routine clinical screening (eg, annual foot exam, 10-g monofilament) and standard glucose testing should be employed before authorizing adjunctive monitoring devices.

    Follow established guidelines (ADA/IWGDF); adjunct devices require evidence of added benefit.

    Technologies with insufficient evidence: Devices lacking sufficient evidence of improved health outcomes (eg, home infrared thermometers for broader use, skin autofluorescence AGE devices like Scout DS, hypoglycemic wristband alarms such as Sleep Sentry, remote monitoring accessories like Dexcom SHARE, and some implantable CGM systems prior to adequate outcome data) may be considered investigational or not medically necessary.

    Coverage contingent on documented clinical justification and evidence of effectiveness.

    Implantable CGM evidence and regulatory status

    Evidence summary and regulatory findings for implantable CGM systems:

    Implantable CGM conclusions: FDA-approved implantable CGM systems (eg, Eversense) have demonstrated acceptable accuracy (MARDs in single-arm studies ~8–11%) and favorable safety profiles in trials; however, evidence that implantable sensors improve glycemic outcomes is limited by small, nonrandomized studies and further outcome data are needed.

    Post-approval studies and documentation of indication are recommended when seeking coverage.

    FreeStyle Libre (flash glucose monitoring) evidence

    Evidence summary for the FreeStyle Libre flash glucose monitoring system:

    FreeStyle Libre findings: FreeStyle Libre (flash CGM) is FDA-approved for adults and demonstrates MARDs in the low-to-mid teens in trials, with most readings in acceptable error grid zones and high user satisfaction; limitations include lack of alarms and variable accuracy at low glucose ranges, and uncertain long-term adherence and outcome benefits.wear up to 10–14 days

    Caution when using readings for insulin dosing due to some >20–30% deviations.

    Remote glucose monitoring / telemonitoring

    Evidence for remote glucose monitoring:

    Remote monitoring findings: Systematic reviews of web-based telemonitoring and health coaching with remote glucose data have shown mixed results; while many studies report improved HbA1c in some contexts, other trials show no significant benefit in quality-of-life or clinical outcomes, leaving the value of remote glucose monitoring services uncertain.

    Coverage decisions for remote monitoring accessories should consider current evidence and demonstrated clinical benefit.

    Supply coverage: usual and high utilization criteria

    Covered quantities and criteria for supplies

    Usual utilization: Members not treated with insulin: up to 100 test strips and up to 100 lancets every 3 months are medically necessary; members treated with insulin: up to 300 test strips and up to 300 lancets every 3 months are medically necessary.100/300 per 3 months

    These are the baseline covered quantities.

    High utilization conditions: Quantities above usual utilization are medically necessary only if ALL of the following are documented: (a) physician documents member/caregiver training and provides a prescription specifying supplies and testing frequency; and (b) treating physician has evaluated diabetes control within 6 months prior to ordering the excess quantities and documented the specific reason; and (c) physician records corroborate that the member is actually testing at the frequency that matches dispensed quantities (eg, testing log or narrative), with ongoing excess utilization documented at least every 6 months.Documentation updated at least every 6 months for ongoing excess utilization

    All three criteria (a)-(c) must be met for high utilization coverage.

    Aetna considers several items to be noncovered convenience items or not medically necessary when billed under medical coverage. Examples explicitly identified include the I-Port Injection Port and hypoglycemic wristband alarms (e.g., Sleep Sentry). Combination devices that pair a home glucose monitor with unrelated functions (for example, blood pressure or cholesterol analyzers or cellular telephones) are also considered convenience items and not separately reimbursed. In addition, cellular-enabled features that merely allow wireless transmission of glucose results are treated as integral to the meter and not separately reimbursable.

    The policy lists specific ICD-10 diagnostic codes that are not covered for the indications addressed in this bulletin: E16.9 (Disorder of pancreatic internal secretion, unspecified) and neonatal hypoglycemia codes P70.3–P70.4. Claims with these principal diagnoses for the CPB-listed indications may be denied.

    The evidence base indicates that continuous glucose monitoring (CGM) has limited durable clinical benefit in unselected individuals. Large/longer-term studies (for example MITRE) and technology-assessment reviews concluded that CGM did not produce sustained HbA1c improvement or meet technology-evaluation criteria when applied to unselected insulin-requiring populations. Device benefit appears to be greatest in selected populations (e.g., nonpregnant adults with type 1 diabetes on intensive insulin regimens).

    Use of CGM in acutely ill inpatients and routine neonatal diagnostic use is not supported by sufficient evidence. Interstitial sensors lose accuracy over time and have a lag (typically ~6–10 minutes), and UpToDate reviews note that although CGM can be reliable and tolerable in neonates, the clinical significance of low interstitial glucose readings and appropriate treatment thresholds remain unclear; therefore routine inpatient or neonatal reliance on CGM outside research settings is premature.

    GlucoWatch labeling and assessments caution that the device is less accurate than fingerstick testing and is intended to supplement, not replace, SMBG. The manufacturer/FDA labeling states users should never make insulin-dosing decisions based solely on GlucoWatch readings and must verify GlucoWatch values with fingerstick measurements; calibration with a fingerstick is required each time the device is worn.

    The Scout DS skin autofluorescence system is described in the policy as a research-use device. The document states there is insufficient evidence that the Scout DS can replace standard diagnostic testing and notes the device is currently used for research purposes only.

    Cellular activation therapy (also called pulsatile intravenous insulin therapy or PIVIT) is listed as lacking evidence of clinical effectiveness. The policy states there is a lack of evidence supporting CAT for treatment of diabetes and considers it unsupported.

    The early validation data cited for the FreeStyle Libre included a very small sample of healthy volunteers (n = 8) in one referenced study. The policy notes this small sample size and absence of diabetic participants as a limitation and indicates larger studies in diabetic populations are needed to confirm findings.

    The policy identifies multiple devices and software considered experimental or investigational and not medically necessary in routine care. Examples include Lasette laser blood glucose monitor, devices for measurement of glycated serum proteins (fructosamine), the PreDx risk score, the Biostator artificial pancreas, the GlucoWatch Biographer, home A1C monitors, mobile diabetes self‑management applications, PDA‑based monitors, infrared thermometry devices (e.g., TempTouch) for routine ulcer prevention, skin autofluorescence AGE measurement systems (e.g., Scout DS), remote monitoring attachments/accessories (e.g., Dexcom SHARE or MiniMed Connect), and cellular activation therapy.

    Fructosamine (glycated serum protein) testing is noted as having unestablished clinical utility; the ADA does not consider it equivalent to HbA1c and randomized data have not demonstrated benefit. Measurement of GAD‑65 antibodies can be useful to distinguish type 1/LADA from type 2 in ambiguous cases, but its value for population screening is unproven because effective prevention strategies are lacking; routine coverage for screening indications is therefore limited.

    Earlier‑generation CGM systems evaluated in randomized trials and technology assessments did not produce durable HbA1c improvement when used broadly in unselected insulin‑requiring individuals. The policy therefore considers use of such earlier CGMs in unselected populations to be not medically necessary absent documented selection criteria that identify patients likely to benefit.

    The document reiterates that routine inpatient CGM use is not supported by sufficient evidence. Sensor durability, accuracy drift, and response lag are cited limitations; CGM use in acutely ill hospitalized patients should be considered investigational or limited to research settings until further evidence becomes available.

    Home A1C monitors and the GlucoWatch Biographer lack prospective trial evidence demonstrating improved clinical outcomes. The policy states GlucoWatch does not eliminate the need for fingerstick testing and randomized trials did not show improved glycemic control with its addition; overall evidence is insufficient to support routine coverage.

    There is insufficient evidence that home infrared thermometry, skin autofluorescence AGE measurement devices, and remote monitoring accessories (for example Dexcom SHARE or MiniMed Connect) consistently improve clinical outcomes. The policy describes these technologies as having limited or uncertain benefit and treats them as investigational or not medically necessary absent stronger evidence or documented clinical need.

    The policy again states that cellular activation therapy is unsupported due to inadequate evidence of clinical effectiveness and therefore is considered not medically necessary.

    When the policy's selection and medical‑necessity criteria are met, a range of CPT and HCPCS codes for CGM services, implantable sensors, and supplies are covered. Examples include 95249, 95250, 95251 for ambulatory short‑term CGM; 0446T–0448T and G0308–G0309 for implantable sensor insertion/removal; and supply/device codes such as A9276–A9278, A4239, and E2103. Coverage of these codes is contingent on documentation that selection criteria in the policy are satisfied.

    Coding: CPT, HCPCS, and ICD-10 Guidance

    Covered CPT/HCPCS codes when selection criteria are metmixedCovered
    0403TPreventive behavior change, intensive program of prevention of diabetes
    82947Glucose; quantitative, blood (except reagent strip)
    82948Glucose; blood, reagent strip
    82950Glucose; post glucose dose (includes glucose)
    82962Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use
    83036Hemoglobin; glycosylated (A1C)
    83037Glycosylated (A1C) by device cleared by FDA for home use
    95249Ambulatory continuous glucose monitoring for minimum of 72 hours; patient-provided equipment...
    95250Ambulatory continuous glucose monitoring for minimum of 72 hours; sensor placement, hook-up...
    95251Analysis, interpretation and report for ambulatory CGM
    1–10 of 20
    1/2
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    0740TRemote autonomous algorithm-based recommendation system for insulin dose calculation and titration
    0741TProvision of software, data collection, transmission, and storage, each 30 days
    81506PreDx Diabetes Risk Score (biochemical assay algorithm reporting a risk score)
    Other HCPCS/CPT codes listedmixed
    A4206Syringe with needle, sterile 1 cc or less
    A4253Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips
    E0607Home blood glucose monitor
    E2101Blood glucose monitor with integrated lancing/blood sample
    S9140Diabetic management program, follow-up visit to non-MD provider
    S1034Artificial pancreas device system
    ICD-10 codes covered if selection criteria are metICD-10Covered
    E10.10 - E10.9Type 1 diabetes mellitus
    E11.00 - E11.9Type 2 diabetes mellitus
    G25.82Stiff-man syndrome
    Covered CPT/HCPCS codes (short-term and implantable CGM & supplies)mixedCovered
    95249Ambulatory continuous glucose monitoring via subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration, patient training, and printout of recording.
    95250Ambulatory continuous glucose monitoring via subcutaneous sensor for a minimum of 72 hours; sensor placement, hook-up, calibration, patient training, removal of sensor, and printout of recording.
    95251Analysis, interpretation and report.
    0446TCreation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training.
    0447TRemoval of implantable interstitial glucose sensor from subcutaneous pocket via incision.
    0448TRemoval of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation.
    A4239Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service.
    Covered HCPCS/Proprietary device codesmixedCovered
    A9276Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day supply.
    A9277Transmitter; external, for use with interstitial continuous glucose monitoring system.
    A9278Receiver (monitor); external, for use with interstitial continuous glucose monitoring system.
    E2103Non-adjunctive, non-implanted continuous glucose monitor or receiver.
    G0308Creation of subcutaneous pocket with insertion of 180 day implantable interstitial glucose sensor, including system activation and patient training.
    G0309Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 180 day implantable sensor, including system activation.
    S1030Continuous noninvasive glucose monitoring device, purchase.
    S1031Continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor.
    S1034Artificial pancreas device system (e.g., low glucose suspend [LGS] feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices.
    S1035Sensor; invasive, for use with artificial pancreas device system.
    1–10 of 12
    1/2
    ICD-10 codes covered if selection criteria are metICD-10
    E08.00 - E13.9Diabetes mellitus (ICD-10 range listed where selection criteria are met).
    E10.10 - E10.9Type 1 diabetes mellitus (ICD-10 range)
    E11.00 - E11.9Type 2 diabetes mellitus (ICD-10 range) — note: considered experimental and investigational for persons not using intensive insulin regimens per document.
    E74.00 - E74.09Glycogen storage diseases (ICD-10 range)
    ICD-10 codes not covered for CPB indicationsICD-10Not Covered
    E16.9Disorder of pancreatic internal secretion, unspecified — listed as ICD-10 codes not covered for indications in the CPB.
    P70.3 - P70.4Iatrogenic and other neonatal hypoglycemia — listed as not covered for indications in the CPB.
    Devices and regulatory status (as described)mixed
    FDA PMA deviceMiniMed 530G System (threshold suspend artificial pancreas device system) — PMA referenced
    FDA 510(k)GlucoWatch Biographer — 510(k) cleared device (historical)
    FDA 510(k)ReliOn NewTek (Express Blood Glucose Monitoring System) — 510(k) cleared
    FDA 510(k)TempTouch infrared thermometer — 510(k) clearance March 2005
    Short-term CGM duration — key thresholds
    Short-term CGM duration72 hours to 1 week; no more than 2 monitoring periods within any 12‑month period
    Typical short-term use indicationsDiagnostic evaluation of hypoglycemia unawareness, repeated daily hypo/hyperglycemia, or diagnosis of nesidioblastosis/PHHI
    Documentation requirementClinical indication and number/dates of monitoring periods must be documented to support ≤2 periods/12 months
    Long-term CGM candidate age
    Age requirement for long-term CGMAdults aged 18 years and older
    Indicated populationsAdults with type 1 or type 2 diabetes using intensive insulin regimens
    Continued use monitoringPrescriber must assess adherence every 6 months for continued long-term use
    Intensive insulin regimen definition
    Definition of intensive insulin regimenMultiple (3 or more) daily insulin injections or insulin pump therapy (continuous subcutaneous insulin infusion)
    Context of useRequired qualifier for long-term CGM coverage in adults
    ImplicationPersons not using an intensive regimen (e.g., T2DM on oral agents) considered investigational for long-term CGM
    Minimum CGM monitoring duration for ambulatory short-term
    Minimum ambulatory short-term monitoring durationMinimum of 72 hours (ambulatory professional/personal CGM)
    Typical maximum short-term durationUp to 1 week for diagnostic indications
    Use noteShort-term (≥72 hours) monitoring intended to detect unrecognized nocturnal hypoglycemia and daily patterning
    CGM sampling frequency
    CGM sampling frequencyEvery 5 minutes (up to 288 readings per day)
    Example devicesGuardian RT and Dexcom systems report readings every 5 minutes
    Clinical implicationHigh-frequency sampling enables trend detection and alarm functions; fingerstick confirmation required before treatment decisions per labeling for some devices
    Sensor use adherence thresholds in analyses
    Adherence threshold used in analyses≥48 days of sensor use or frequent use (e.g., ~6.7 days/week) associated with better outcomes in some trials
    Real-world adherence metricHigh percent usage (daily wear) linked to greater HbA1c improvement in select studies
    Study contextManufacturer-funded and observational studies reported associations between days worn/scan frequency and glycemic metrics
    Average sensor use over 12 months
    Average sensor use over 12 months (observational study)30% average use (first 3 months 37%; last 3 months 27%)
    ImplicationSensor wear tends to decrease over time in real‑world settings, limiting long‑term benefit
    Source studyNorgaard et al. 12‑month multicenter observational study of sensor‑augmented pump therapy
    Infrared foot temperature alert threshold (hot spot)
    Infrared foot temperature alert thresholdA side‑to‑side skin temperature difference ≥4°F (4 degrees Fahrenheit) flags a 'hot spot'
    Recommended actionWhen ≥4°F difference noted, patients were instructed to reduce activity and contact care per trial protocols
    Predictive valueElevated temperature differences associated with increased risk of ulceration in RCTs
    Implantable CGM hypoglycemia alarm trigger
    Implantable CGM hypoglycemia alarm triggerAlarms were set to trigger when glucose < 70 mg/dL in implantable CGM home‑use studies
    Performance metricsReported hypoglycemia alarm sensitivity ~77% and specificity ~96% in home‑use implantable sensor study
    Sensor lifespan noteMean sensor life reported ~87 ± 7 days (implantable sensors) in home‑use study
    Hypoglycemia definition in Sleep Sentry studies
    Hypoglycemia definition used in Sleep Sentry studiesHypoglycemia defined as ≤ 3 mmol/L (≈ 54 mg/dL) in some study analyses
    Device limitationsSleep Sentry detected ~2/3 of lows but produced numerous false alarms in pediatric/adult studies
    Clinical implicationHigh false alarm rate and skin reactions limit utility; clinical usefulness unproven
    Quarterly supplies (test strips, lancets)
    Usual quarterly supplies — non‑insulin usersUp to 100 test strips and up to 100 lancets every 3 months
    Usual quarterly supplies — insulin usersUp to 300 test strips and up to 300 lancets every 3 months
    High‑utilization documentationQuantities above these limits require physician documentation: (a) training/prescription, (b) physician evaluation within 6 months, and (c) corroborating testing logs or narrative updated ≥ every 6 months

    Provider Actions: Authorization, Documentation, and Billing

    Prior Authorization

    Prior authorization for CGM and implantable sensors

    Certain CGM and implantable sensor CPT/HCPCS codes are covered only when the policy's selection/medical necessity criteria are met; claims for these codes should be supported by documentation that the member meets the CPB selection criteria prior to billing.

    • Covered codes include examples such as 95249, 95250, 95251, 0446T-0448T, G0308-G0309, A9276-A9278, A4239, and E2103.
    • Ensure policy selection criteria (short-term diagnostic or long-term therapeutic indications) accompany claims for these codes.
    Prior Authorization

    Procedure/device codes requiring criteria

    Specific procedure and durable device codes for implantable sensors and CGM systems require that the policy’s selection criteria be met; when billing these procedure/device codes, providers must ensure the medical record documents the applicable selection criteria.

    • Listed procedure codes include 0446T, 0447T, 0448T, G0308, G0309.
    • Device/supply codes include A9276, A9277, A9278, A4239 and S1030–S1037.
    Prior Authorization

    Prior authorization likely for defined populations

    Technology assessments and guidelines emphasize limiting CGM use to populations with demonstrated benefit (for example, non-pregnant adults with type 1 diabetes using multiple daily injections or pump therapy); when prescribing CGM for these populations, document indications and education/training provided.

    • ADA and technology assessments support CGM for adults with type 1 diabetes on intensive insulin regimens and recommend assessing readiness and providing robust education.
    • Document that the member is in a population supported by evidence (e.g., adult type 1 diabetes on ≥3 daily injections or pump).
    Denial Risk

    Inpatient CGM use

    Use of CGM in inpatient or acutely ill settings is not supported by sufficient evidence; inpatient CGM use should be considered investigational or limited to research settings unless and until further studies establish clinical benefit.

    • The ADA (2007) and systematic reviews note lack of data for acutely ill inpatients; providers should avoid routine inpatient CGM outside research.
    Note

    PMA device noted — prior authorization not specified

    The MiniMed 530G System is FDA-approved (PMA) as a threshold-suspend artificial pancreas device system; the CPB does not specify payer prior authorization rules for PMA devices, so providers should follow applicable plan-level requirements.

    • MiniMed 530G is FDA PMA-approved for threshold suspend functionality; plan-specific prior authorization policies are not detailed in this excerpt.
    Prior Authorization

    Prior authorization for implantable CGM and accessories

    Implantable CGM systems and remote monitoring accessories may be considered investigational or have limited evidence of outcome benefit; such devices may require prior authorization and supporting clinical justification when requested for coverage.

    • Eversense implantable CGM has FDA approval but clinical outcome benefits are limited; remote accessories (e.g., Dexcom SHARE) lack demonstrated outcome improvements and may be denied.
    • Providers should be prepared to supply evidence of clinical need when requesting coverage for implantable CGM or remote monitoring accessories.
    Prior Authorization

    Prior authorization for implantable CGM

    Use of implantable CGM requires documentation of the device indication and that insertion/removal was performed as an outpatient procedure; providers should submit the outpatient procedure notes and clinical rationale when requesting coverage.

    • Eversense involves outpatient implantation and FDA reviewed insertion/removal procedure safety; document procedure details and device indication in the medical record.
    • Include clinical study or FDA approval rationale if coverage is requested for implantable CGM.
    Documentation Required

    Prior authorization / documentation requirements for high utilization

    Quarterly usual supplies are limited (non-insulin users up to 100 strips/lancets; insulin users up to 300 strips/lancets); dispensing quantities above these thresholds require physician documentation meeting the CPB’s three required criteria.

    • For quantities above usual utilization, physician must document: (a) training/prescription for device and testing frequency; (b) evaluation of diabetes control within 6 months with rationale; (c) evidence that member is testing at the frequency that corroborates dispensed quantities, with updates at least every 6 months.
    Prior Authorization

    Prior authorization may be required per plan provisions

    Plan provisions govern coverage administration; providers should follow the member’s specific plan rules because prior authorization requirements may apply at the plan level even if not specified in the CPB.

    • Clinical Policy Bulletins are partial descriptions of plan benefits and do not replace plan documents; check member plan rules for prior authorization requirements.
    Step Therapy

    Step requirements for long-term CGM

    Long-term CGM coverage is limited to adults (≥18 years) using intensive insulin regimens (multiple [≥3] daily injections or insulin pump therapy); CGM for persons with type 2 diabetes not using intensive regimens is considered experimental/investigational.

    • Document that the member is ≥18 years and using an intensive insulin regimen (≥3 daily injections or pump) when requesting long-term CGM coverage.
    • Type 2 diabetes patients not on intensive regimens are not covered for long-term CGM per CPB.
    Step Therapy

    Therapy sequencing considerations

    When CGM is integrated with insulin pump therapies (sensor-augmented systems), these are incremental to care and require structured training and monitoring; document the training and follow-up plan when initiating combined therapies.

    • Combined pump/CGM systems require patient education and monitoring; document readiness and training per ADA and technology assessment recommendations.
    Note

    Consider sequencing insulin delivery changes

    Initiation of pump therapy can confound assessment of CGM benefit; when both are started, document the sequencing rationale and clinical justification to support coverage decisions.

    • Trials combining pump initiation with CGM make it difficult to attribute benefit; provide rationale if therapies are initiated concurrently.
    Documentation Required

    Professional CGM for diagnostic evaluation

    Short-term professional CGM may be used diagnostically to detect unrecognized hypoglycemia (often nocturnal) when conventional SMBG is insufficient; document the diagnostic indication and limit duration to 72 hours–1 week, with no more than two monitoring periods per 12 months.

    • Document specific diagnostic indication (e.g., hypoglycemia unawareness, recurrent symptomatic hypoglycemia) and the planned monitoring duration (72 hours to 1 week).
    • CPB limits short-term professional CGM to a maximum of 2 periods within 12 months.
    Step Therapy

    No explicit step therapy requirements specified

    This excerpt does not specify any formal step therapy mandates; providers should note that no explicit step therapy requirements are stated in the CPB text.

    • Although no explicit step therapy mandates are listed, usual utilization thresholds and selection criteria functionally guide coverage decisions.
    Step Therapy

    Step through standard care first

    Before authorizing novel monitoring devices for foot ulcer prevention or other adjunctive technologies, consider standard care first (annual foot exam, 10-g monofilament screening) and document attempts at conventional management.

    • Standard screening and preventive care (10-g monofilament, annual exam) should be documented prior to using adjunctive devices.
    • Document prior outpatient or self-monitoring strategies and rationale for advancing to device-based monitoring.
    Note

    Step therapy

    The CPB does not state explicit step therapy mandates for CGM or related devices; providers should follow the selection criteria and documentation requirements outlined in the policy when requesting coverage.

    • No formal step therapy sequence is imposed by the CPB; clinical indications, device-specific criteria, and documentation guide coverage.
    Billing Rule

    Utilization thresholds as step

    Usual utilization thresholds (100 strips/lancets per 3 months for non-insulin users; 300 per 3 months for insulin users) act as baseline coverage quantities; quantities above these thresholds require the CPB’s documented justification (physician training confirmation, recent evaluation, corroborating testing logs).

    • Use the CPB’s three documentation criteria to support higher quarterly supply requests: prescription/training, evaluation within 6 months, and testing log or narrative.
    • Ongoing excess utilization requires updated documentation at least every 6 months.
    Documentation Required

    Documentation for diabetes self-care programs

    Providers must order diabetes self-care education programs and include a physician-signed statement that the service is needed; programs must be delivered by recognized healthcare professionals and designed to educate about medically necessary diabetes self-care.

    • Ensure the medical record contains the physician order and signed statement of medical necessity for the self-care program.
    • Document that the program personnel are recognized healthcare professionals (physician, RD, RN, pharmacist).
    Documentation Required

    Documentation for short-term CGM

    Short-term CGM requests must document the diagnostic indication (e.g., hypoglycemia unawareness, repeated daily hypo/hyperglycemia, nesidioblastosis/PHHI) and specify monitoring duration (72 hours–1 week) with a limit of two periods per 12 months.

    • Include documentation of symptoms and prior conventional testing that was insufficient to characterize hypoglycemia.
    • Specify intended monitoring duration (72 hours to 1 week) and prior short-term CGM use within the past 12 months.
    Documentation Required

    Documentation for long-term CGM

    Long-term CGM therapeutic use requires documentation that the patient is an adult (≥18 years) using an intensive insulin regimen (≥3 daily injections or insulin pump) and either is not meeting glycemic targets or is experiencing hypoglycemia; continued use requires evidence of benefit or prescriber assessment of adherence every six months.

    • Document age, insulin regimen details (≥3 injections/day or pump), current glycemic control, and history of hypoglycemia or hypoglycemia unawareness.
    • For ongoing coverage, document either improved glycemic control or decreased hypoglycemia, or record prescriber adherence assessment at least every 6 months.
    Billing Rule

    Coding and documentation crosswalk

    Use of specific CPT/HCPCS codes for CGM procedures, supplies, implantable sensors, and accessories should be supported by meeting the CPB selection criteria; ensure the claim documentation crosswalks the billed codes to the applicable selection criteria.

    • Examples of codes requiring selection criteria include 95249–95251, 0446T–0448T, A4239, A9276–A9278, G0308–G0309, S1030–S1037, and E2103.
    • Attach supporting clinical documentation showing which CPB criteria are satisfied when submitting claims.
    Documentation Required

    Document patient readiness and training

    Assess and document patient readiness, education, training, and adherence when prescribing CGM; evidence of individualized training and follow-up supports medical necessity.

    • Document that robust diabetes education and support were provided and that the patient’s ability to use and adhere to CGM was assessed.
    • Record follow-up plans and adherence assessments in the medical record.
    Documentation Required

    Recommended supporting data

    When submitting CGM clinical data to support coverage (short-term or long-term), include paired sensor readings with capillary blood glucose values, monitoring durations (e.g., 72-hour or 14-day), and event counts such as hypoglycemic episodes or time-in-range summaries.

    • Provide sensor logs paired with SMBG calibration checks and summaries of hypoglycemic events or time-in-range metrics.
    • Include duration of monitoring and summary interpretation to justify changes in management.
    Documentation Required

    Calibration/documentation requirement (device labeling)

    Follow device labeling for calibration and documentation requirements (for example, GlucoWatch labeling requires fingerstick calibration each time the device is worn); include calibration records when relevant.

    • For devices that require calibration, document fingerstick calibration readings and dates in the medical record.
    • Note device-specific limitations (e.g., GlucoWatch cannot be used alone for insulin-dosing decisions).
    Documentation Required

    Supporting clinical evidence documentation

    For wound-temperature monitoring and implantable CGM, providers should document supporting clinical evidence such as measured reliability, sensor lifespan, sensitivity/specificity, and clinical justification to demonstrate medical necessity.

    • Include study results or device performance metrics (e.g., sensor life span, MARD, sensitivity/specificity) when requesting coverage for investigational devices.
    • Document potential procedure-related adverse events and outpatient procedure notes for implantable sensors.
    Documentation Required

    Procedure and device documentation

    Document procedural details and device safety for implantable CGM insertions/removals; include outpatient procedure notes, informed consent, and any device-related adverse event monitoring in the medical record.

    • Record insertion/removal operative notes, device lot/serial numbers, and post-procedure follow-up.
    • Document counseling on device risks (infection, bleeding, skin reactions) as noted in FDA review.
    Documentation Required

    Required physician documentation for >usual supply quantities

    When requesting quantities of supplies exceeding usual utilization limits, the physician must document (a) training/prescription for device and testing frequency, (b) evaluation of diabetes control within 6 months prior to the order with rationale, and (c) evidence that the member is testing at a frequency that corroborates dispensed quantities; renew this documentation at least every six months for ongoing excess utilization.

    • Maintain a testing log or narrative that demonstrates actual testing frequency.
    • Keep documentation of the physician’s recent evaluation and explicit reason for additional supplies in the medical record.
    Note

    Providers are responsible for medical advice and plan verification

    Providers are responsible for medical advice and treatment; the CPB is a partial description of plan benefits and not a contract — verify member plan benefits and prior authorization rules before ordering devices or services.

    • Check the member’s plan documents for coverage specifics, prior authorization requirements, and whether supplies are covered under pharmacy or medical benefits.
    Denial Risk

    Non-covered/convenience items may be denied

    Items listed as non-covered or convenience features (for example, I-Port, hypoglycemic wristband alarms, and cellular-enabled wireless attachments) risk denial if billed to medical coverage or when plan excludes them; verify coverage pathway (medical vs pharmacy) and plan exclusions before ordering.

    • Aetna does not cover wireless transmission attachments or provides no additional reimbursement for integrated wireless features considered convenience.
    • Confirm whether a device is considered a convenience item or excluded by the member’s plan prior to billing.
    Denial Risk

    Coding-based denial risks

    Claims with certain ICD-10 principal diagnoses (for example, E16.9 and P70.3–P70.4) are listed as not covered for the CPB indications and may be denied; ensure appropriate diagnosis coding that aligns with the CPB selection criteria when submitting claims.

    • E16.9 (Disorder of pancreatic internal secretion, unspecified [nesidioblastosis]) and P70.3–P70.4 (neonatal hypoglycemia codes) are listed as not covered for CPB indications.
    • Use diagnosis codes that match the covered indications (e.g., E10.x, E11.x) and document selection criteria.
    Denial Risk

    Population-specific limits may trigger denial

    Evidence is insufficient for broad CGM use in children, adolescents, and pregnant women; use in these populations may not meet technology assessment criteria and could be denied unless strong selection criteria and documentation are provided.

    • CTAF and other assessments found conclusive benefit mainly in adults and noted adherence issues in younger populations; document clinical rationale thoroughly if prescribing in these subgroups.
    Denial Risk

    Inpatient use unsupported

    Use of CGM and related accessories in the inpatient/acute setting is unsupported by current evidence and may be considered investigational outside research; expect potential denial for inpatient claims for CGM unless part of an approved study.

    • ADA and systematic reviews note insufficient inpatient data; document research protocol if device use is part of a study.
    Denial Risk

    Research-use devices

    Devices used for research only (for example, Scout DS for AGE measurement) and interventions without demonstrated clinical benefit may not meet coverage criteria; provide clinical evidence if requesting coverage for research-use technologies.

    • Scout DS system is currently used for research and is not intended to replace standard diagnostic tests; coverage is unlikely without demonstrated clinical effectiveness.
    Denial Risk

    High utilization documentation requirements

    Dispensing quantities of supplies that exceed utilization guidelines without the CPB-required physician documentation (training/prescription, evaluation within 6 months, and testing logs/narrative) may lead to denial of coverage.

    • If requesting higher-than-usual quarterly supplies, include the three required documentation elements and ensure records are updated at least every 6 months for ongoing excess use.
    Note
    Note
    Note
    Note
    Note

    Background and Evidence Summary

    Background: Continuous glucose monitoring (CGM) is described in the policy for both short‑term diagnostic use and long‑term therapeutic use. Short‑term (professional) CGM is defined as monitoring for 72 hours to 1 week for diagnostic indications such as hypoglycemia unawareness, recurrent daily hypo/hyperglycemia, or evaluation of conditions like nesidioblastosis/PHHI. Long‑term CGM is intended for adults (≥18 years) on intensive insulin regimens (≥3 daily injections or insulin pump therapy) who are not meeting glycemic targets or who experience problematic hypoglycemia; ongoing use requires reassessment and documentation of benefit or adherence.

    Implantable CGM systems (for example Eversense/Senseonics) have received regulatory approval for adult use and clinical studies report acceptable accuracy (MARDs in the single digits to low teens) and favorable safety profiles in small prospective trials. However, the policy notes that available studies are limited by sample size and study design, and while accuracy and short‑term safety are supported, evidence that implantable sensors improve long‑term glycemic outcomes remains limited.

    FreeStyle Libre (flash glucose monitoring) is described as a factory‑calibrated, intermittently scanned system approved for adult use that can be worn up to 10–14 days without routine SMBG calibration. Accuracy studies reported MARDs generally in the low to mid teens with a large proportion of values in acceptable error grid zones and positive user experience; nonetheless limitations include absence of real‑time alarms and some inaccuracy at low glucose ranges, and longer‑term outcome benefits and adherence remain uncertain.

    Remote glucose monitoring / telemonitoring (for example, Dexcom SHARE and other web‑based telemonitoring programs) enable data transmission to caregivers or health systems, but systematic reviews and trials have yielded mixed results. The policy highlights a lack of consistent evidence that remote monitoring improves clinical outcomes or quality of life; as a result, accessory devices that provide remote transmission are generally considered convenience features and are not separately reimbursed in routine care absent clear demonstrated benefit.

    Definitions and Key Terms

    Short-term CGM — definition and limits
    Short-term CGM — definitionMonitoring for 72 hours to 1 week for diagnostic indications (e.g., hypoglycemia unawareness, recurrent daily hypo/hyperglycemia)
    Use limitsNo more than 2 short‑term monitoring periods within 12 months for diagnostic purposes
    DocumentationIndication and monitoring period documented to support diagnostic use
    Long-term CGM — definition and coverage criteria
    Long-term CGM — definitionMonitoring for greater than 1 week for therapeutic management in adults (≥18 years) using intensive insulin regimens
    Coverage qualifiersCovered when adults on ≥3 daily injections or pump therapy are not meeting glycemic targets or experience hypoglycemia (including unawareness)
    Continued useContinued coverage if improved control or prescriber documents adherence assessment every 6 months
    Diabetic test strips and meters — definition
    Diabetic test strips and meters — definitionDevices and disposable strips used for fingerstick blood glucose testing; glucose oxidase on strips reacts with blood glucose and is measured by a glucose meter
    ExamplesCommon brands include Abbott, FreeStyle, Accu‑Chek, Bayer Contour, OneTouch series
    Use noteStrips and meters are used to obtain reference fingerstick values to calibrate or confirm CGM readings
    Fructosamine (glycated serum protein)
    Fructosamine (glycated serum protein)Laboratory test measuring average glucose over prior 2–3 weeks; ADA states it is not equivalent to HbA1c and clinical utility remains unestablished
    Evidence noteRandomized trial found home fructosamine monitoring resulted in higher HbA1c at 3 and 6 months in one study
    Clinical useMay be considered in selected situations but not a routine substitute for HbA1c per ADA
    GAD-65 antibodies — definition and clinical use notes
    GAD‑65 antibodies — clinical roleAutoantibodies to glutamic acid decarboxylase used as a predictive marker for type 1 diabetes and to help distinguish LADA from type 2 when clinical history is ambiguous
    Screening limitationValue of population screening unproven because no preventive measures have been established
    Diagnostic useUseful in selected high‑risk individuals and ambiguous presentations
    PreDx Diabetes Risk Score
    PreDx Diabetes Risk Score — definitionProprietary multibiomarker algorithm combining seven biomarkers plus age and sex to estimate 5‑year risk of developing diabetes
    Score rangeGenerates a risk score (1–10) indicating likelihood of developing diabetes within 5 years
    AvailabilityOffered by specific laboratories; used for risk stratification rather than diagnosis
    Hypoglycemia unawareness — definition and notes
    Hypoglycemia unawareness — definitionReduced ability to perceive hypoglycemia; reversible with avoidance of hypoglycemia and can be addressed with behavioral training
    Clinical significanceIndication for short‑term diagnostic CGM and potential qualifier for long‑term CGM in adults
    AssessmentDocumented episodes or clinical history support use of CGM for unawareness evaluation
    Sensor-augmented pump therapy — definition
    Sensor‑augmented pump therapy — definitionCombination of continuous glucose monitoring with continuous subcutaneous insulin infusion (CSII) or insulin pump therapy
    Clinical evidenceTrials (e.g., STAR 3) showed improved HbA1c with sensor‑augmented pump therapy vs multiple daily injections in selected settings
    ConsiderationBenefit seen in controlled trials with intensive support; generalizability to routine care may be limited
    Artificial pancreas / closed-loop system — definition
    Artificial pancreas / closed‑loop system — definitionClosed‑loop system integrating an insulin pump, real‑time CGM, and a control algorithm to calculate and deliver insulin (and/or glucagon)
    Use noteRepresents an automated insulin delivery approach; early systems mainly research; modern hybrid closed‑loop systems FDA‑cleared for certain ages
    ExamplesBiostator (research), MiniMed 770G/530G (threshold‑suspend/ hybrid closed‑loop systems)
    CGM sensor limitations
    CGM sensor limitationsSubcutaneous interstitial glucose sensors correlate with blood glucose but lose accuracy over time, require periodic replacement (e.g., many sensors changed every 3 days), and exhibit a 6–10 minute lag, especially during rapid glucose changes
    Clinical implicationLag and declining accuracy can limit reliability in rapidly changing glucose or hypoglycemic ranges; fingerstick confirmation often required
    MaintenancePeriodic sensor replacement and calibration are necessary per device labeling
    Artificial pancreas (closed-loop) — alternate definition
    Artificial pancreas (alternate definition)System integrating insulin pump, real‑time CGM, and a computing algorithm to coordinate sensing and insulin delivery
    FunctionCalculates insulin dosing and can suspend or adjust insulin based on CGM readings
    Regulatory noteSome components (threshold‑suspend) have FDA PMA approval (e.g., MiniMed 530G)
    Threshold-suspend (low glucose suspend) feature
    Threshold‑suspend (low glucose suspend) feature — definitionA pump/CGM feature that suspends insulin delivery for up to two hours when sensor glucose reaches a preset low threshold and the user does not respond to an alarm
    Regulatory exampleMiniMed 530G is FDA‑approved and incorporates threshold‑suspend functionality
    Clinical effectTrials demonstrated reductions in nocturnal hypoglycemia with threshold‑suspend systems
    Hot spot (infrared thermometry) — definition
    Hot spot (infrared thermometry) — definitionA same‑site temperature increase of 4°F or greater compared with the contralateral foot site, considered predictive of impending ulceration
    Device exampleTempTouch infrared thermometer measures plantar skin temperature and flags ≥4°F differences
    Clinical protocolPatients instructed to reduce activity and contact care when hot spot detected
    Skin autofluorescence (SAF) — definition
    Skin autofluorescence (SAF)Non‑invasive measurement of tissue accumulation of advanced glycation end products (AGEs) using autofluorescence spectroscopy
    Intended useProposed as risk predictor for abnormal glucose tolerance; not a replacement for oral glucose tolerance testing
    Evidence statusInsufficient evidence for routine clinical use; currently research‑oriented
    Remote glucose monitoring (Dexcom SHARE) — definition
    Remote glucose monitoring (Dexcom SHARE)Accessory that transmits CGM data wirelessly to designated recipients' smartphones to enable remote viewing and alerts
    CapabilityUploads glucose data to secure server; up to 5 designated recipients can receive alerts
    EvidenceLack of evidence that remote monitoring (Dexcom SHARE) improves health outcomes
    Flash CGM (FreeStyle Libre)
    Flash CGM (FreeStyle Libre) — definitionFactory‑calibrated, intermittently scanned interstitial glucose monitoring system worn up to 10–14 days that provides on‑demand readings without automatic alarms
    Wear durationAfter 12‑hour start‑up, sensor can be worn up to 10 days (FDA‑cleared for adults) per labeling
    LimitationsNo real‑time alarms and variable accuracy in low glucose ranges; long‑term outcome benefits uncertain
    Implantable CGM (Eversense/Senseonics) — definition
    Implantable CGM (Eversense/Senseonics)Subcutaneously implanted glucose sensor paired with external transmitter and mobile app providing continuous glucose data for up to ~90 days per sensor
    Regulatory statusEversense approved by FDA for adults 18+; implantable sensor worn up to 90 days
    Clinical considerationsRequires outpatient insertion/removal procedure and documentation; accuracy studies show favorable MARD but outcome benefit evidence limited
    Flash Glucose Monitoring — additional definition entry
    Flash Glucose Monitoring (FreeStyle Libre) — additional noteMeasures interstitial glucose and provides trend arrows; studies report variable accuracy and examples of low sensor glucose occurrences following higher capillary BG readings
    Study sizesCited studies include sample sizes of 241 and 224 insulin‑treated participants in European trials
    Clinical cautionExercise caution when relying on sensor readings for insulin dosing in hypoglycemic ranges
    Hybrid closed-loop system (MiniMed 770G)
    Hybrid closed‑loop system (MiniMed 770G) — definitionInsulin delivery system that monitors glucose and automatically adjusts basal insulin delivery based on glucose readings; MiniMed 770G approved for users aged 2 years and older
    Related device noteMiniMed 530G (threshold‑suspend) is an earlier FDA‑approved system for users ≥16 years with low‑glucose suspend capability
    Clinical implicationHybrid closed‑loop systems represent advanced automated insulin delivery but patient selection and training remain important

    Policy Dates and Revision History

    1995-10-20effective

    Policy became effective (Clinical Policy Bulletin No. 0070: Diabetes Tests, Programs and Supplies).

    2023-08-09last_review

    Policy underwent last clinical review (Last Review recorded for the bulletin).

    2024-01-11next_reviewLatest

    Next scheduled policy review date recorded in the bulletin.